Abstract
Developing a so-called "green economy" garners more support in the current climate of uncertainty and danger. Since the beginning of the 21st century, we have recognized that the drive to develop the economy causes irreparable harm to the planet's ecosystem. After the Covid pandemic, a new intermediate industry, the biopharmaceutical industry, has emerged to reduce the tension between the human ecology and the earth's ecosystem. This industry devised a successful response to the health, economic, and social issues of the pandemic age. This paper aims to examine the financial performance of two renowned biopharmaceutical companies, Pfizer and Moderna, which have been permitted to distribute the mRNA vaccine worldwide. This paper concludes the investigation into the stock performance of these two companies prior to and throughout COVID. Besides, examination of the technology market index, market volatility, and investor sentiment reveals the various fluctuations. In addition, the data reveals an effect of contagion between the two enterprises and the technology market. Thus, the research gives useful information for the development of public health economics, policy, and administration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Advances in Economics, Management and Political Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
